Letter Asks Congress for Nearly $500 Million to Sustain BRAIN Initiative

Why It Matters

Sustaining BRAIN funding preserves the pipeline from basic neuroscience discoveries to clinical treatments, protecting U.S. leadership in brain research. A budget shortfall could stall innovative projects and diminish economic returns from biotech advances.

Key Takeaways

• $468 million request matches 2022 BRAIN funding level
• Cures Act funding ends FY2026, creating budget uncertainty
• FY2024 saw 40% cut, FY2025 projected deeper decline
• Congressional briefing scheduled April 22 to showcase breakthroughs
• Continued investment crucial for future brain disorder therapies

Pulse Analysis

The BRAIN Initiative, launched in 2013, was designed to accelerate discovery of neural circuits and translate those insights into new treatments for brain disorders. Backed initially by the 21st Century Cures Act and sustained by NIH base funding, the program has delivered high‑resolution imaging tools, innovative data‑sharing platforms, and early‑stage therapeutic candidates. Over the past decade, its budget peaked at $680 million in FY2023, reflecting growing confidence that federal investment can catalyze breakthroughs in neurology, psychiatry, and neurotechnology.

In early 2024, a coalition of 150 research institutions, advocacy groups, and industry partners sent a formal letter to Congress demanding $468 million for the upcoming fiscal year—essentially restoring the level the initiative received in 2022. The request addresses a looming funding gap caused by the scheduled expiration of Cures Act appropriations after FY2026 and a static base‑budget that produced a 40 percent cut in FY2024 and an even steeper projected decline for FY2025. Without supplemental appropriations, many multi‑year grant commitments risk being delayed or cancelled, jeopardizing ongoing projects.

The American Brain Coalition plans a congressional briefing on April 22 to showcase tangible outcomes—advanced neuroimaging methods, open‑source data repositories, and early clinical trials—that stem directly from BRAIN funding. Demonstrating these returns aims to persuade lawmakers that continued investment not only safeguards scientific momentum but also fuels a burgeoning biotech sector poised to generate high‑value jobs and therapeutic pipelines. As global competition intensifies, maintaining the United States’ leadership in brain research hinges on stable, predictable federal support; the $468 million request represents a critical inflection point for the nation’s neuro‑innovation ecosystem.